Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 521

1.

Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial.

Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, Walker DJ, Chappell AS, Arnold LM.

Pain. 2008 Jun;136(3):432-44. doi: 10.1016/j.pain.2008.02.024. Epub 2008 Apr 18.

PMID:
18395345
2.

A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.

Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ.

Arthritis Rheum. 2004 Sep;50(9):2974-84.

3.

A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder.

Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, Wernicke JF.

Pain. 2005 Dec 15;119(1-3):5-15. Epub 2005 Nov 17.

PMID:
16298061
4.

Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.

Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF.

J Psychiatr Res. 2005 Jan;39(1):43-53.

PMID:
15504423
5.

Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range.

Mallinckrodt CH, Prakash A, Andorn AC, Watkin JG, Wohlreich MM.

J Psychiatr Res. 2006 Jun;40(4):337-48. Epub 2005 Nov 4.

PMID:
16271726
6.

Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.

Brecht S, Courtecuisse C, Debieuvre C, Croenlein J, Desaiah D, Raskin J, Petit C, Demyttenaere K.

J Clin Psychiatry. 2007 Nov;68(11):1707-16.

PMID:
18052564
7.

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.

Eur Neuropsychopharmacol. 2004 Dec;14(6):457-70.

PMID:
15589385
8.

Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA.

J Clin Psychiatry. 2002 Mar;63(3):225-31.

PMID:
11926722
9.

Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder.

Arnold LM, Hudson JI, Wang F, Wohlreich MM, Prakash A, Kajdasz DK, Chappell AS.

Clin J Pain. 2009 Jul-Aug;25(6):461-8. doi: 10.1097/AJP.0b013e318197d4e4.

PMID:
19542792
10.

Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.

Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.

Depress Anxiety. 2007;24(1):41-52.

PMID:
16845641
11.

A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.

Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME.

J Psychiatr Res. 2008 Jan;42(1):22-34. Epub 2007 Apr 18.

PMID:
17445831
12.

Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.

Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.

Curr Med Res Opin. 2007 Jun;23(6):1303-18. Epub 2007 Apr 27.

PMID:
17559729
13.

Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Perahia DG, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ.

Eur Psychiatry. 2006 Sep;21(6):367-78. Epub 2006 May 11.

PMID:
16697153
14.

Efficacy and safety of duloxetine in patients with chronic low back pain.

Skljarevski V, Desaiah D, Liu-Seifert H, Zhang Q, Chappell AS, Detke MJ, Iyengar S, Atkinson JH, Backonja M.

Spine (Phila Pa 1976). 2010 Jun 1;35(13):E578-85. doi: 10.1097/BRS.0b013e3181d3cef6.

PMID:
20461028
15.

Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials.

Kornstein SG, Wohlreich MM, Mallinckrodt CH, Watkin JG, Stewart DE.

J Clin Psychiatry. 2006 May;67(5):761-70.

PMID:
16841626
16.

Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study.

Arnold LM, Zhang S, Pangallo BA.

Clin J Pain. 2012 Nov-Dec;28(9):775-81. doi: 10.1097/AJP.0b013e3182510295.

PMID:
22971669
17.

Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia.

Mease PJ, Russell IJ, Kajdasz DK, Wiltse CG, Detke MJ, Wohlreich MM, Walker DJ, Chappell AS.

Semin Arthritis Rheum. 2010 Jun;39(6):454-64. doi: 10.1016/j.semarthrit.2008.11.001. Epub 2009 Jan 18.

PMID:
19152958
18.

Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.

Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA.

J Clin Psychiatry. 2002 Apr;63(4):308-15.

PMID:
12000204
19.
20.

A comparison of initial duloxetine dosing strategies in patients with major depressive disorder.

Whitmyer VG, Dunner DL, Kornstein SG, Meyers AL, Mallinckrodt CH, Wohlreich MM, Gonzales JS, Greist JH.

J Clin Psychiatry. 2007 Dec;68(12):1921-30.

PMID:
18162024
Items per page

Supplemental Content

Write to the Help Desk